1. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389-397. [PubMed]

2. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-1249. [PubMed]

3. Kinkel R, O’Connor P, Kremenchutzky M. CHAMPS study reanalysis based on new clinically isolated syndrome classification criteria. Neurology. 2007;68(suppl 1):A162.

4. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-127. [PubMed]

5. National Multiple Sclerosis Society. Research/Clinical Update: Study suggests Copaxone treatment reduces risk of developing MS. Available at: http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=69. Accessed March 22, 2008.

6. A prospective study looking at the use of Rebif in subjects with clinically isolated syndrome. Available at: http://clinicaltrials.gov/ct2/show/NCT00287079. Accessed February 6, 2008.

7. Clinical trial comparing treatment of relapsing-remitting multiple sclerosis (RRMS) with two doses of glatiramer acetate. Available at: http://clinicaltrials.gov/ct2/show/NCT00337779. Accessed February 1, 2008.

8. Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M; 9006 Study Group. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology. 2007;68:939-944. [PubMed]

9. Simsarian JP, Pardo G, Barbarash O, et al. Safety and immunogenicity of Rebif^® New Formulation (RNF) a new subcutaneous formulation of interferon beta-1a 44 mcg three times weekly: 1-year results of a phase IIIb study in patients with relapsing-remitting multiple sclerosis. Neurology. 2007;68(suppl 1):A274.

10. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology. 2002;59:1496-1506. [PubMed]

11. Bayer HealthCare AG. BEYOND study: results do not support regulatory filing for Betaferon 500 mcg. Available at: http://www.viva.vita.bayerhealthcare.com/index. Accessed March 22, 2008.

12. National Multiple Sclerosis Society. MS Trial Alert: NIH-Sponsored Combination Therapy Study Recruiting Patients with MS. Available at: http://www.nationalmssociety.org/site/PageServer?pagename=HOM_RES_research_2006jan27. Accessed February 6, 2008.

13. Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) Combi Rx. Available at: http://clinicaltrials.gov/ct2/show/NCT00211887?term=relapsingremitting+multiple+sclerosis&rank=9. Accessed March 22, 2008.

14. Arnold D, Bar-Or A, Freedman M, Gazda S, Pantich H, Vollmer T. Reductions in Gd enhancing lesions observed with glatiramer actate following a brief and low dose course of mitoxantrone in patients with relapsing remitting multiple sclerosis (RRMS) are paralleled by favorable effects on MRI markers of disease burden and black hole evolution. Neurology. 2007;68(suppl 1):A281.

15. Vollmer T, Campagnolo D, Panitch H, Bar-Or A, Arnold D. Reductions in MRI disease activity and relapse rates observed after induction of short-term immunosuppression with mitoxantrone followed by long-term glatiramer acetate (GA) are maintained at 24 months in patients with relapsing-remitting multiple sclerosis (RRMS). Neurology. 2007;68 (suppl 1):A279.

16. Edan G, Comi G, Lebrun C, et al. The French-Italian mitoxantrone interferon beta trial: a 3-year randomised study. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

17. Montanari E, Manneschi L, Pesci I. ASPIRE interferon beta-1b in combination with azathioprine for secondary progressive multiple sclerosis: a 2-year, double blind, randomised, multicentre, pilot study. EDSS, MSQOL54 and safety data. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

18. Havrdova E, Zivadinov R, Krasensky J, et al. Intramuscular interferon beta-1a, azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis: 5-year clinical efficacy. Neurology. 2007;68(suppl 1):A277.

19. Metz L, Li D, Traboulsee A, et al. Glatiramer acetate combined with minocycline reduces the number of lesions compared to glatiramer acetate alone. Neurology. 2007;68(suppl 1):A84.

20. Mikol DD, Barkhof F, Chang P, et al. The REGARD trial: a randomised assessor-blinded trial comparing interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

21. Wolansky L, Cook S, Skurnick J, et al. Betaseron vs. Copaxone in MS with triple-dose gadolinium and 3-T MRI Endpoints (BECOME): announcement of final primary study outcome. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

22. Cadavid D, Wolansky L, Cook S, et al. Betaseron versus copaxone in multiple sclerosis with triple-dose gadolinium and 3 Tesla MRI Endpoints (BECOME): announcement of secondary clinical outcomes. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

23. Fox E, Mayer L, Sullivan H, et al. Two-year results with alemtuzumab in patients with active relapsing-remitting multiple sclerosis who have failed licensed beta interferon therapies. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

24. Compston DAS. A peculiar lesion in the cord with atrophy––is multiple sclerosis an inflammatory or neurodegenerative disease? Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

25. Montalban X, Wynn D, Kaufman M, Wang M, Fong A. Preliminary CHOICE results: a phase 2, randomised, double-blind, placebo-controlled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

26. Waubant E, Hauser S, Arnold DL, et al. Safety and efficacy of rituximab in adults with relapsing-remitting multiple sclerosis: results of a phase II placebo- controlled, multicentre trial through 48 weeks. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic,October 11-14, 2007.

27. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124-1140. [PubMed]

28. Efficacy and safety of fingolimod (FTY720) in patients with relapsing remitting multiple sclerosis (FREEDOMS II). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00355134. Accessed February 1, 2008.

29. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T; Laquinimod in Relapsing MS Study Group. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005;64:987-991. [PubMed]

30. Comi G, Abramsky O, Arbizu T, et al. The effect of two doses of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, placebo-controlled study. Neurology. 2007;68(suppl 1):A84.

31. Safety and efficacy of orally administered laquinimod for treatment of relapsing remitting multiple sclerosis (RRMS). Available at: http://clinicaltrials.gov/ct2/show/NCT00509145. Accessed February 1, 2008.

32. O’Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66:894-900. [PubMed]

33. Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients with Multiple Sclerosis (TEMSO). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00134563. Accessed February 1, 2008.

34. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000;54:1145-1155. [PubMed]

35. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA. 1996;93:1716-1720. [PubMed]

36. Giovannoni G, Comi G, Cook S, et al. The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

37. Montalban X, Cohen BA, Jeffery DR, Leist TP, Moses H, Musch B, on behalf of the ONWARD study group (Oral Cladribine Added on to Rebif New Formulation in Subjects With Active Multiple ScleRosis StuDy). Oral cladribine added to interferon beta-1a for active multiple sclerosis: a 96-week, double- blind, placebo-controlled phase IIb study. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

38. Kappos L, Gold R, Miller D, et al. Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG0012 for the treatment of relapsing-remitting multiple sclerosis. Neurology. 2007;68(suppl 1):A276.

39. Gold R, Fox R, Dawson K, O’Neill G, Yang M, Panzara M. Two phase 3 studies to determine the efficacy and safety of BG00012, a novel, oral fumaric acid derivative, in patients with relapsing multiple sclerosis. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

40. Panzara M, Belcher G, Kooijmans M, Kim R, Lynn F, Bozic C. Use of natalizumab in patients with relapsing multiple sclerosis: updated safety results from TOUCHTM and TYGRIS. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

41. Ebers G, Goodin D, Li D, et al. The Interferon Beta-1b 16-Year Long-Term Follow-up Study: predictive clinical and magnetic resonance imaging markers. Presented at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic, October 11-14, 2007.

42. Avonex 15 Year Long Term Follow-up Study (15yASSURANCE). Available at: http://clinicaltrials.gov/ct2/show/NCT00525343. Accessed February 1, 2008.

43. Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry. 2008;79:52-56. [PubMed]